These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

510 related articles for article (PubMed ID: 24319222)

  • 41. MGUS and smoldering multiple myeloma: update on pathogenesis, natural history, and management.
    Rajkumar SV
    Hematology Am Soc Hematol Educ Program; 2005; ():340-5. PubMed ID: 16304401
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Understanding biology to tackle the disease: Multiple myeloma from bench to bedside, and back.
    Bianchi G; Anderson KC
    CA Cancer J Clin; 2014; 64(6):422-44. PubMed ID: 25266555
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Expression of the IL-6 receptor alpha-chain (CD126) in normal and abnormal plasma cells in monoclonal gammopathy of undetermined significance and smoldering myeloma.
    Salem DA; Korde N; Venzon DJ; Liewehr DJ; Maric I; Calvo KR; Braylan R; Tembhare PR; Yuan CM; Landgren CO; Stetler-Stevenson M
    Leuk Lymphoma; 2018 Jan; 59(1):178-186. PubMed ID: 28540748
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Smoldering multiple myeloma 40 years later: a story of unintended disease.
    Yavorkovsky LL
    Expert Rev Hematol; 2021 Feb; 14(2):149-153. PubMed ID: 33430658
    [No Abstract]   [Full Text] [Related]  

  • 45. Smoldering multiple myeloma current treatment algorithms.
    Rajkumar SV; Kumar S; Lonial S; Mateos MV
    Blood Cancer J; 2022 Sep; 12(9):129. PubMed ID: 36064707
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A contribution to examination of propidium iodide and annexin V plasma cells indices in multiple myeloma.
    Scudla V; Ordeltova M; Bacovsky J; Vytrasova M; Sumna E; Martinek A; Horak P
    Neoplasma; 2003; 50(5):363-71. PubMed ID: 14628090
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Is It Possible to Predict Tumor Progression Through Genomic Characterization of Monoclonal Gammopathy and Smoldering Multiple Myeloma?
    Testa U; Leone G; Pelosi E; Castelli G; De Stefano V
    Mediterr J Hematol Infect Dis; 2024; 16(1):e2024044. PubMed ID: 38882455
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Smoldering multiple myeloma - Past, present, and future.
    Mann H; Katiyar V; Varga C; Comenzo RL
    Blood Rev; 2022 Mar; 52():100869. PubMed ID: 34312016
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
    Rajkumar SV; Lacy MQ; Kyle RA
    Blood Rev; 2007 Sep; 21(5):255-65. PubMed ID: 17367905
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical characteristics and outcomes in biclonal gammopathies.
    Mullikin TC; Rajkumar SV; Dispenzieri A; Buadi FK; Lacy MQ; Lin Y; Dingli D; Go RS; Hayman SR; Zeldenrust SR; Russell SJ; Lust JA; Leung N; Kapoor P; Kyle RA; Gertz MA; Kumar SK
    Am J Hematol; 2016 May; 91(5):473-5. PubMed ID: 26840395
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Smoldering Multiple Myeloma: Observation Versus Control Versus Cure.
    Rajkumar SV; Bergsagel PL; Kumar S
    Hematol Oncol Clin North Am; 2024 Apr; 38(2):293-303. PubMed ID: 38158241
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Advances in understanding monoclonal gammopathy of undetermined significance as a precursor of multiple myeloma.
    Weiss BM; Kuehl WM
    Expert Rev Hematol; 2010 Apr; 3(2):165-74. PubMed ID: 20473362
    [TBL] [Abstract][Full Text] [Related]  

  • 53. SOHO State of the Art Updates and Next Questions: Diagnosis and Management of Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma.
    Schmidt T; Gahvari Z; Callander NS
    Clin Lymphoma Myeloma Leuk; 2024 Oct; 24(10):653-664. PubMed ID: 38641486
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Smoldering Multiple Myeloma: Emerging Concepts and Therapeutics.
    Sundararajan S; Kumar A; Korde N; Agarwal A
    Curr Hematol Malig Rep; 2016 Apr; 11(2):102-10. PubMed ID: 26894382
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The yin-yang effects of immunity: From monoclonal gammopathy of undetermined significance to multiple myeloma.
    Yi Z; Ma T; Liu J; Tie W; Li Y; Bai J; Li L; Zhang L
    Front Immunol; 2022; 13():925266. PubMed ID: 35958625
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The Role of T Cell Immunity in Monoclonal Gammopathy and Multiple Myeloma: From Immunopathogenesis to Novel Therapeutic Approaches.
    Lagreca I; Riva G; Nasillo V; Barozzi P; Castelli I; Basso S; Bettelli F; Giusti D; Cuoghi A; Bresciani P; Messerotti A; Gilioli A; Pioli V; Colasante C; Vallerini D; Paolini A; Maccaferri M; Donatelli F; Forghieri F; Morselli M; Colaci E; Leonardi G; Marasca R; Potenza L; Manfredini R; Tagliafico E; Trenti T; Comoli P; Luppi M
    Int J Mol Sci; 2022 May; 23(9):. PubMed ID: 35563634
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
    Kyle RA; San-Miguel JF; Mateos MV; Rajkumar SV
    Hematol Oncol Clin North Am; 2014 Oct; 28(5):775-90. PubMed ID: 25212882
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Long-term follow-up of patients with monoclonal gammopathy of undetermined significance after kidney transplantation.
    Naina HV; Harris S; Dispenzieri A; Cosio FG; Habermann TM; Stegall MD; Dean PG; Prieto M; Kyle RA; Rajkumar SV; Leung N
    Am J Nephrol; 2012; 35(4):365-71. PubMed ID: 22473253
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Smoldering multiple myeloma.
    Gao M; Yang G; Kong Y; Wu X; Shi J
    Biomed Res Int; 2015; 2015():623254. PubMed ID: 26000300
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Monoclonal gammopathy of undetermined significance: why identification of these patients and assessment of their skeletons is important.
    Berenson JR; Yellin O
    Clin Lymphoma Myeloma; 2009 Aug; 9(4):311-5. PubMed ID: 19717382
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.